New research reveals that people who come off blockbuster GLP-1 drugs like Mounjaro or Wegovy tend to recover reduced body mass much more quickly than those who end traditional lifestyle plans.
Findings released in a leading medical journal demonstrates that while overweight people can lose substantial amounts of their total mass while on the medication, the weight is regained at an estimated rate of nearly a kilo each month once they quit.
"Users buying these treatments should be aware of the risk of quick rebound weight gain when the therapy concludes," warns researcher Dr. Susan Jebb.
Such speed of recovery implies a return to pre-treatment weight in about one and a half years.
Weighing Approaches
The study, which examined 37 of studies involving over 9,000 of participants, contrasted the effects of these new drugs with other pills.
Scientists emphasize that individuals who lose weight through dieting usually have a less rapid creep back—perhaps 0.1 kg a month—once they finish.
Explaining the Quick Rebound
Doctors propose the way of the injections is key to understanding the accelerated rebound.
GLP-1 drugs copy a body's own chemical called glucagon-like peptide-1, which moderates appetite.
"Artificially providing the hormone levels several times higher than normal could lead to the body to produce less of its endogenous GLP-1, and may also lessen responsiveness to its actions," noted Dr. Adam Collins, a dietetics researcher.
"Withdrawal of this hormone supplement results in hunger is no longer kept in check, making overeating far more likely."
An Ongoing Issue?
The NHS advise the jabs for people with weight-linked medical conditions, accompanied by recommended diet and exercise modifications.
Professionals contend that, considering the significant potential of relapse, the treatment should be considered life-long.
This view is echoed by pharmaceutical companies, who note that the findings "underscore the persistent nature of obesity," similar to managing diseases like high blood pressure.
User Experiences
Users who have stopped the jabs describe a sudden return of hunger.
"I experienced a switch that goes on and you're instantly extremely hungry," said a patient.
This challenge is exacerbated if individuals have not developed lasting dietary or behavioural changes during therapy.
Significant Use
Figures suggest that a significant number of adults in the UK have tried weight-loss jabs in the last 12 months, with interest continuing to grow.
- Use is more common among females than males.
- The middle-aged age group shows the greatest level of interest.
- A large proportion access the drugs through private healthcare rather than public health services.
In conclusion, researchers stress that while GLP-1 drugs are potent agents for shedding pounds, they are not a magic cure and lasting health benefits hinges on ongoing behavioural changes.
